Bernard Coulie, MD, PhD

Bernard is the CEO and President of Pliant Therapeutics, a NASDAQ-listed biopharmaceutical company focused on developing novel treatments for rare and life-threatening fibrotic diseases. His journey with CMT began in 1997 when his son was diagnosed with CMT1A at 2 years of age. Bernard joins the CMTA’s Board with the goal of sharing his experience as a father of a CMT patient who is now a thriving adult thanks to a life-long commitment to physical therapy and a spirit of perseverance.

Bernard holds an M.D. and Ph.D. from the University of Leuven, Belgium, is board-certified in internal medicine, and earned an MBA from Vlerick Management School, Leuven, Belgium. With over 20 years of experience in senior leadership roles within the biopharmaceutical industry, including serving as CEO and Chief Medical Officer at ActoGeniX, Bernard is dedicated to leveraging his medical and executive expertise to further the CMTA’s mission and drive impactful advancements that will bring treatments and a cure to CMT.

Bernard currently resides in San Francisco. He is an avid cyclist, an enthusiastic but intermediate skier, and a certified San Francisco City Guide.